Some what reassuring that the RT-AR001 drug platform will progress "in conjunction with and oversight from Ridgeway Therapeutics" which puts Dr. Hislop in charge of getting it done. He has experience in negotiating the waters of the FDA and has proven experience in these matters. No one at NSPX has a clue on moving the drug platforms forward. So now its wait and let DR. Hislop do what he does and see what happens.
News 
Market Data 
Discover 
